WO1980002111A1 - Process and composition for treating disorders by administering lecithin - Google Patents
Process and composition for treating disorders by administering lecithin Download PDFInfo
- Publication number
- WO1980002111A1 WO1980002111A1 PCT/US1980/000342 US8000342W WO8002111A1 WO 1980002111 A1 WO1980002111 A1 WO 1980002111A1 US 8000342 W US8000342 W US 8000342W WO 8002111 A1 WO8002111 A1 WO 8002111A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lecithin
- choline
- brain
- acetylcholine
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
Definitions
- This invention relates to a process for the adminis ⁇ tration of lecithin in the absence of a drug in order to treat human disorders by increasing acetylcholine levels in brain and other tissues.
- diseases which affect acetyl- choline-containing neurons in the brain or other tissues, and which are treated by drugs that cause undesired side effects by diminishing acetylcholine's release; there also exist diseases now treated by other drugs in which the potency and/or efficacy of the drugs could be improved by combining them with choline or natural or synthetic com ⁇ pounds that dissociate to form choline in order thereby to enhance the release of acetylcholine.
- diseases include both those primarily involving the brain (e.g., diseases of higher cortical functions; psychiatric illnesses; move ⁇ ment disorders) and those involving the peripheral nervous system (e.g., neuromuscular disorders).
- Tardive dys inesia is a particularly common movement disorder associated with inadequate release of brain acetylcholine as a result of drug administrations for the initial brain disease (e.g., phychosis) .
- Tardive dyskinesia is a choreic movement dis ⁇ order characterized by involuntary twitches in the tongue, lips, jaw and extremities. It typically occurs in sus ⁇ ceptible persons after chronic ingestion of neuroleptic drugs and may involve an imbalance in the postulated recip ⁇ rocal relation between dopaminergic and cholinergic neurons in the basal ganglions.
- catechola ine synthesis e.g., alpha-methyl-p-tyrosine5 , deplete the brain of monoamines (e.g., reserpine, tetra- benazine) or antagonize dopamine's actions on synaptic ' receptors (e.g., pherothiazines, galoperidol) often suppres tardive dyskinesia, whereas drugs that indirectly stimulate dopamine receptors (e.g., amphetamine, levodopa) often exacerbate the abnormal movements.
- monoamines e.g., reserpine, tetra- benazine
- antagonize dopamine's actions on synaptic ' receptors e.g., pherothiazines, galoperidol
- drugs that indirectly stimulate dopamine receptors e.g., amphetamine, levodopa
- Drugs assumed to increase the amount of acetylcholine within brain synapses e.g., physostigmine, deanol
- acetylcholine also tend to suppress the chorea of tardive dyskinesia
- anticholinergics e.g., scopolamine
- choline administered by injection or by dietary supplementation increases blood choline levels in the rat; this, in turn, increases choline levels in cholinergic neurons within the brain and elsewhere in the body, thereby accelerating the synthesis of acetylcholine, increasing tissue acetylcholine levels, and increasing the amounts of acetylcholine released into brain synapses.
- oral doses of choline or of lecithin, a naturally-occurring compound that dissociates to choline were found to cause dose-related increases in blood choline levels of sufficient magnitude (based on the studies on rats) to enhance brain acetylcholine synthesis and release; choline* levels in the cerebrospinal fluid also rose in parallel.
- This invention is based upon the discovery that
- lecithin when administered alone, optimizes physiological functions and restores impaired physiological functions in situations associated with inadequate cholinergi ⁇ trans ⁇ mission such as tardive dyskinesia, manic-depressive states or other psychiatric diseases, memory impairment, familial ataxias or the like.
- the lecithin can be administered orally such as in tablet, capsule, granules or liquid form or parenterally by intravenous, intramuscular or sub ⁇ cutaneous injection.
- lecithin is administered to a patient without a drug in order to in ⁇ crease blood levels of choline, and thereby to increase the level of acetylcholine in the brain.
- the acetyl ⁇ choline is synthesized from choline and acetyl CoA in a reaction catalyzed by choline acetyltransterase (CAT) . It has been found that the administration of lecithin alone is useful for the treatment of physiological functions associated with inadequate cholinergic transmission.
- the lecithin can be administered as lecithin with either saturated or unsaturated fatty acid side chains.
- the lecithin is administered so that a choline level of at leas about 10-25 nanomoles/ml and usually between about 10 and 50 n moles/ml is attained in the patient's blood stream.
- lecithin in a liquid carrier it is administered in amounts of between about 0.1 and 100 g/day.
- lecithin is administered in granular form, as a tablet or in a capsule, it is- employed in amounts of between about 0.1 and 100 g/day, usually between about 30 and 50 g/day.
- lecithin is not available as a pure compound and is available in admixture with other phospholipids wherein the lecithin comprises about 20-30 weight percent of the mixture.
- a patient who was not taking medication, but who had suffered memory loss, but who did not suffer from any other brain dysfunction or from any psychiatric disease was treated with lecithin. Prior to the lecithin treatment, he was tested for memory quotient and intelligence quotient by the Wechsler Memory & Intelligence tests; his memory quotient was 122.
- Lecithin obtained from the Nattermann Corporation and which comprises 80% lecithin was orally administered to the subject at a dosage of 109 every 8 hours over a period of 6 weeks.
- the dosages were prepared by mixing the lecithin in foods.
- Plasma samples for choline measurements were collected from the subject before the lecithin trial began and 6 weeks later during lecithin ingestion; plasma samples were separated, frozen and assayed for choline content by a con ⁇ ventional radioenzymatic method. Before treatment, plasma choline levels were 12.g + 1.1 nmol per milliliter. After lecithin ingestion, plasma choline levels in blood obtained 4 hours after a lecithin dose increased to 30.3 + 2.7 nmol per milliliter (P ⁇ .01). During the 6th week of lecithin ingestion at a time the plasma choline level was significantly elevated, his memory quotient improved to 140.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/027,209 US4221784A (en) | 1979-04-05 | 1979-04-05 | Process and composition for treating disorders by administering lecithin |
| US27209 | 1979-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1980002111A1 true WO1980002111A1 (en) | 1980-10-16 |
Family
ID=21836350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1980/000342 Ceased WO1980002111A1 (en) | 1979-04-05 | 1980-03-31 | Process and composition for treating disorders by administering lecithin |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4221784A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0026223A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS56500374A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1980002111A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3228629A1 (de) * | 1982-07-31 | 1984-02-02 | Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß | Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung |
| EP0125900A1 (en) * | 1983-05-16 | 1984-11-21 | Massachusetts Institute Of Technology | A pharmaceutical composition for use in treating neurological disease or aging |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63734A (en) * | 1981-09-04 | 1985-07-31 | Yeda Res & Dev | Lipid fraction,its preparation and pharmaceutical compositions containing same |
| GB8331808D0 (en) * | 1983-11-29 | 1984-01-04 | Unilever Plc | Food product |
| CH661438A5 (it) * | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| US5135922A (en) * | 1984-06-15 | 1992-08-04 | Med-Tal, Inc. | Prevention and treatment of microbial infection by phosphoglycerides |
| US5051410A (en) * | 1988-09-01 | 1991-09-24 | Massachusetts Institute Of Technology | Method and composition for enhancing the release of neurotransmitters |
| US5001117A (en) * | 1989-03-07 | 1991-03-19 | Pharmacaps, Inc. | Use of lecithin to restore olfaction and taste |
| US6312703B1 (en) | 1998-02-06 | 2001-11-06 | Lecigel, Llc | Compressed lecithin preparations |
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8143234B2 (en) * | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| DK1870103T3 (da) * | 1998-07-31 | 2010-01-11 | Massachusetts Inst Technology | Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse |
| US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| DE10340740A1 (de) * | 2003-09-04 | 2005-03-31 | Degussa Food Ingredients Gmbh | Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis |
| US7645795B2 (en) * | 2004-09-21 | 2010-01-12 | BodyBio, Inc | Method for treating amyotrophic lateral sclerosis |
| CA2645645C (en) * | 2005-05-23 | 2015-07-14 | Massachusetts Institute Of Technology | Compositions containing pufa and methods of use thereof |
| BRPI0817387A2 (pt) * | 2007-11-02 | 2015-09-08 | Massachusetts Inst Technology | métodos de conformidade de suplementação dietária de uridina e uso dos mesmos |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0000924A1 (de) * | 1977-08-30 | 1979-03-07 | Hoechst Aktiengesellschaft | Heterocyclische Phenyläther und Verfahren zu ihrer Herstellung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2064727A (en) * | 1931-05-02 | 1936-12-15 | Buer Carl Heinz | Process for the manufacture of stable preparations having a high content of commercial lecithin |
| US3088871A (en) * | 1959-05-19 | 1963-05-07 | Riker Laboratories Inc | Process of stimulating the central nervous system |
| DE2004409A1 (de) * | 1970-01-31 | 1971-09-02 | Keimdiat GmbH, 8900 Augsburg | Natürlicher Wirkstoff fur pharmazeuti sehe und diätetische Zwecke |
-
1979
- 1979-04-05 US US06/027,209 patent/US4221784A/en not_active Expired - Lifetime
-
1980
- 1980-03-31 WO PCT/US1980/000342 patent/WO1980002111A1/en not_active Ceased
- 1980-03-31 JP JP50102980A patent/JPS56500374A/ja active Pending
- 1980-10-23 EP EP80900850A patent/EP0026223A1/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0000924A1 (de) * | 1977-08-30 | 1979-03-07 | Hoechst Aktiengesellschaft | Heterocyclische Phenyläther und Verfahren zu ihrer Herstellung |
Non-Patent Citations (1)
| Title |
|---|
| CHEMICAL ABSTRACTS, Vol. 88, 1978, Columbus, Ohio, USA, R.J. WURTMAN et al. "Lecithin consumpion raises scrum-free choline levels page 224, Abstract No. 60447 C pp. 68-9. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3228629A1 (de) * | 1982-07-31 | 1984-02-02 | Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß | Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung |
| EP0125900A1 (en) * | 1983-05-16 | 1984-11-21 | Massachusetts Institute Of Technology | A pharmaceutical composition for use in treating neurological disease or aging |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56500374A (cg-RX-API-DMAC7.html) | 1981-03-26 |
| US4221784A (en) | 1980-09-09 |
| EP0026223A1 (en) | 1981-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4221784A (en) | Process and composition for treating disorders by administering lecithin | |
| US4351831A (en) | Process and composition for treating disorders by administering isoxsurpine and choline | |
| DE68912331T2 (de) | Erniedrigung der zellvermehrung und steigerung der killerzellenaktivität. | |
| CA1238280A (en) | Pharmaceutical compositions containing bilobalid | |
| DE2907778C2 (cg-RX-API-DMAC7.html) | ||
| DE69828881T2 (de) | Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen | |
| US4636494A (en) | Process and composition for treating disorders by administering amphetamine and choline | |
| US20120329765A1 (en) | Medicinal targeted local lipolysis | |
| EP0552240A1 (en) | New method of treating depression | |
| US4609647A (en) | Cytidyl diphosphocholine-drug composition and process | |
| MC1552A1 (fr) | Procede de fabrication de compositions anti-herpes synergiques | |
| AU2004285264A1 (en) | Medicamentously targeted local lipolysis | |
| US4346085A (en) | Process and composition for treating disorders by administering amphetamine and choline | |
| US4569929A (en) | Cytidyl diphosphocholine-drug composition | |
| US4156013A (en) | Method for treating patients suffering from anxiety neurosis and anxietylike neurosis, and alcoholism | |
| EP0001924B2 (en) | Pharmaceutical composition for administering choline | |
| US4346084A (en) | Process and composition for treating disorders by administering lithium and choline | |
| US4355027A (en) | Process and composition for treating disorders by administering piracetam and choline | |
| US5407924A (en) | Method of treating pain using inositol triphosphate | |
| EP0217258B1 (en) | The use of choline or choline releasing compounds for reducing the perception of fatigue | |
| US4430330A (en) | Process and composition for treating disorders by administering a phenothiazine and choline | |
| US4456598A (en) | Process and composition for treating disorders by administering a butyrophenone and a choline | |
| EP0271023A2 (de) | Verwendung von Dihydrophenylaminosäurederivaten und diese enthaltende Arzneimittel zur Immunmodulation und Cytostase | |
| CN111514290B (zh) | 一种葫芦素组合物及其用途 | |
| DE19650778A1 (de) | Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Designated state(s): JP |
|
| AL | Designated countries for regional patents |
Designated state(s): GB |